Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly
(Thomson Reuters ONE) -
Novartis International AG /
Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at
World Health Assembly
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Framework aims to improve effectiveness of responses to future pandemics and
outlines principles for influenza virus and benefit-sharing
* Novartis reiterates commitment to global pandemic preparedness, including
support for affordable and equitable access to pandemic vaccines for
developing countries
Basel, May 19, 2011 - Novartis welcomes the decision to endorse the Pandemic
Influenza Preparedness Framework (PIP Framework) at the Sixty-fourth World
Health Assembly. The PIP Framework sets out the roles and commitments of
different stakeholders, including the World Health Organization (WHO) and
vaccine manufacturers, in pandemic preparedness.
The PIP Framework provides additional transparency and certainty to the
influenza virus and benefit-sharing process for all stakeholders. It will
strengthen the WHO GISN (Global Influenza Surveillance Network), which is
critical for rapid vaccine production during a pandemic outbreak. The Framework
is also an important step towards affordable and equitable access to pandemic
vaccines for developing countries. Public stakeholders and industry will work
together to implement access strategies for low-income countries with the
objective of building a sustainable supply for all. Beyond its contribution to
the GISN, Novartis plans to dedicate a portion of its global pandemic
manufacturing capacity to developing countries based on a tiered-pricing model.
"At Novartis we remain dedicated to working with the WHO and other stakeholders
to further strengthen global pandemic preparedness." said Andrin Oswald, Head of
Novartis Vaccines and Diagnostics. "Where supported by demand for seasonal
vaccines, we are collaborating with local partners to expand production capacity
in developing countries. Furthermore, we continue to invest in innovation to
make influenza vaccine production faster and more affordable, such as using our
adjuvant technology that can increase our production output during a pandemic by
up to four-fold."
As a leading vaccine manufacturer, Novartis was at the forefront of the global
pandemic response efforts during the 2009 A(H1N1) influenza pandemic. In
addition to facilitating access to pandemic vaccines for developing countries
through a tiered-pricing model, Novartis transferred vaccine and adjuvant
production technologies to enable localized production and increase global
production capacity.
"We now look forward to an open dialogue with the other stakeholders and working
together to achieve a comprehensive and balanced implementation of the Framework
based on agreed principles," added Oswald.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "aims," "future," "commitment," "will," "plans,"
"dedicated," "can," "look forward to," or similar expressions, or by express or
implied discussions regarding the development, approval, manufactured and
distribution of potential future pandemic flu vaccines or regarding potential
future revenues from such vaccines. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that any future pandemic
flu vaccines will be developed, approved, manufactured or distributed in any
market. Nor can there be any guarantee that such vaccines will achieve any
particular levels of revenue in the future. In particular, management's
expectations regarding such vaccines could be affected by, among other things,
unexpected disease patterns; unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; unexpected manufacturing difficulties; competition in general;
government, industry and general public pricing pressures; the company's ability
to obtain or maintain patent or other proprietary intellectual property
protection; the impact that the foregoing factors could have on the values
attributed to the Novartis Group's assets and liabilities as recorded in the
Group's consolidated balance sheet, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
About Novartis
Novartis provides healthcare solutions that address the evolving needs of
patients and societies. Focused solely on healthcare, Novartis offers a
diversified portfolio to best meet these needs: innovative medicines, eye care,
cost-saving generic pharmaceuticals, consumer health products, preventive
vaccines and diagnostic tools. Novartis is the only company with leading
positions in these areas. In 2010, the Group's continuing operations achieved
net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1
billion excluding impairment and amortization charges) was invested in R&D
throughout the Group. Headquartered in Basel, Switzerland, Novartis Group
companies employ approximately 119,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visithttp://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Liz Power
Novartis Global Media Relations Novartis Vaccines and Diagnostics
+41 61 324 7999 (direct) +1 617 871 7985 (direct)
+41 79 593 4202 (mobile) +1 617 583 3015 (mobile)
eric.althoff(at)novartis.com elizabeth.power(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please
contact:journalisthelp(at)thenewsmarket.com
Novartis Investor Relations
Central phone: |+41 61 324 7944 | |
----------------------+-----------------+---------------+---------------------
Susanne Schaffert |+41 61 324 7944 |North America: |
----------------------+-----------------+---------------+---------------------
Pierre-Michel Bringer|+41 61 324 1065 |Richard Jarvis |+1 212 830 2433
----------------------+-----------------+---------------+---------------------
Thomas Hungerbuehler |+41 61 324 8425 |Jill Pozarek |+1 212 830 2445
----------------------+-----------------+---------------+---------------------
Isabella Zinck |+41 61 324 7188 |Edwin Valeriano|+1 212 830 2456
----------------------+-----------------+---------------+---------------------
| | |
----------------------+-----------------+---------------+---------------------
e-mail: investor.relations(at)novartis.com|e-mail:
|investor.relations(at)novartis.com
----------------------------------------+-------------------------------------
|
--- End of Message ---
Novartis International AG
Postfach Basel
WKN: 904278;ISIN: CH0012005267;
Media Release (PDF):
http://hugin.info/134323/R/1517375/453903.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1517375]
Unternehmensinformation / Kurzprofil:
Datum: 19.05.2011 - 17:30 Uhr
Sprache: Deutsch
News-ID 54838
Anzahl Zeichen: 9808
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
